Novavax, Inc (NVAX) concluded trading on Wednesday at a closing price of $8.30, with 3.99 million shares of worth about $33.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -60.42% during that period and on December 04, 2024 the price saw a loss of about -1.31%. Currently the company’s common shares owned by public are about 160.15M shares, out of which, 153.02M shares are available for trading.
Stock saw a price change of -5.14% in past 5 days and over the past one month there was a price change of -8.99%. Year-to-date (YTD), NVAX shares are showing a performance of 72.92% which increased to 44.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.53 but also hit the highest price of $23.86 during that period. The average intraday trading volume for Novavax, Inc shares is 6.22 million. The stock is currently trading -1.26% below its 20-day simple moving average (SMA20), while that difference is down -18.78% for SMA50 and it goes to -19.35% lower than SMA200.
Novavax, Inc (NASDAQ: NVAX) currently have 160.15M outstanding shares and institutions hold larger chunk of about 58.98% of that.
The stock has a current market capitalization of $1.33B and its 3Y-monthly beta is at 2.04. It has posted earnings per share of -$2.26 in the same period. It has Quick Ratio of 0.93. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 4.84% while standing at 7.53% over the month.
Stock’s fiscal year EPS is expected to rise by 73.75% while it is estimated to increase by 107.16% in next year. EPS is likely to grow at an annualized rate of 37.90% for next 5-years, compared to annual growth of 11.55% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on July 30, 2024 offering an Underweight rating for the stock and assigned a target price of $8 to it. On May 10, 2024, BofA Securities Upgrade their recommendations, while on August 09, 2023, B. Riley Securities Upgrade their ratings for the stock with a price target of $15. Stock get a Market perform rating from TD Cowen on April 20, 2023.
